We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
Tilray Brands, Inc.
Consumer Staples · Pharmaceuticals
Structural: Largest Canadian LP by revenue, #1 cannabis market share in Canada and Germany medical, top-5 US craft brewer post the 2023 ABInBev brand acquisition ($85M cash for 8 craft beer brands). Beverage-alcohol segment (~$200M annualized) provides non-cannabis cashflow + US distribution rails ready for federal cannabis legalization.
International medical cannabis exposure via Aphria Germany + Tilray Portugal + CC Pharma EU distribution.
Bull case:
- US federal rescheduling (Schedule III) or SAFE Banking removes 280E tax penalty and unlocks institutional capital
- German adult-use rollout (legalized April 2024) drives EU medical-to-rec optionality where Tilray holds #1 medical share
- Beverage portfolio + distribution rails = ready-made US cannabis-infused beverage platform once legal
- $250M+ cash + convertible notes restructured; survival risk lower than smaller LPs
- M&A optionality: HEXO + Truss + ABI craft brand consolidation playbook
Bear case:
- Canadian rec market remains oversupplied with price compression; segment gross margin pressured
- Beverage segment growth flat ex-acquisitions; craft beer category in secular decline
- Chronic share dilution (~946M shares vs ~100M at 2018 IPO) funds losses, not growth
- US legalization timeline keeps slipping; rescheduling stuck in DEA review
- Persistent adjusted EBITDA losses on a GAAP basis; cash burn requires continued capital raises
No major news in the last 7 days for TLRY - only listicles and opinion pieces, which we filter out by default. See everything anyway.
No key levels recorded for this ticker.